MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-.

Business Wire • Aug 14, 2026

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

PRNewsWire • Aug 10, 2026

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

Business Wire • Aug 8, 2026

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Aug 7, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses. Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.

GlobeNewsWire • Aug 6, 2026

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

GlobeNewsWire • Aug 6, 2026

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (2.

Business Wire • Aug 5, 2026

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

GlobeNewsWire • Aug 4, 2026

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss.

PRNewsWire • Aug 3, 2026

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026